Boston Scientific Corporation

1555 articles with Boston Scientific Corporation

• Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope

  5/25/2021

  Boston Scientific Corporation announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

• Boston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference

  5/24/2021

  Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37 th Annual Strategic Decisions Conference on Friday, June 4, 2021 .

• Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System

  5/18/2021

  Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage and permanent pacemaker implementation, of the Boston Scientific ACURATE neo2™ Aortic Valve System within the investigator-initiated Early neo2 Registry1 and ITAL-neo Registry2 studies.

• Boston Scientific Announces May Conference Schedule

  5/3/2021

   Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

• Boston Scientific Announces Conference Call Discussing First Quarter 2021 Results and Participation in Truist Securities 2021 Life Sciences Summit

  3/26/2021

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28, 2021 at 8:00 a.m. EDT . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brenna

• 

  Boston Scientific to Pay $189 Million in Vaginal Mesh Lawsuit

  3/24/2021

  Boston Scientific’s settlement was not an admission of misconduct or liability. In a brief statement cited by Reuters, the company said the financial agreement was in its shareholder’s best interest.

• Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres

  3/18/2021

   Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma

• Boston Scientific Announces Agreement To Acquire Lumenis LTD. Surgical Business From Baring Private Equity Asia

  3/3/2021

  Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD

• Baring Private Equity Asia Announces Agreement to Sell Lumenis' Surgical Business to Boston Scientific for USD1.07 billion

  3/3/2021

  Baring Private Equity Asia retains ownership of fast-growing Aesthetics and Vision businesses, to reinvest part of deal proceeds to accelerate growth

• Boston Scientific Announces February and March 2021 Conference Schedule

  2/12/2021

   Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

• Boston Scientific Announces Results For Fourth Quarter And Full Year 2020

  2/3/2021

  Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational 1 basis and (8.0) percent on an organic 2 basis, all compared to the prior year period.

• Boston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System

  1/22/2021

   Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System.

• Boston Scientific Announces Agreement To Acquire Preventice Solutions, Inc.

  1/21/2021

  Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities

• Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S.

  1/14/2021

  Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha ™ portfolio of Spinal Cord Stimulator (SCS) systems.

• Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2020

  1/12/2021

   Boston Scientific Corporation (NYSE:  BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8) percent on a reported basis, approximately (8.3) percent on an operational 1 basis and appr

• Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2020 Results

  1/4/2021

  Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . Mike Mahoney , chairman and chief executive officer, will present at 8:20 a.m. EST . At approximately 8:40 a.m. EST , Mahoney will be joined by Dan Brennan , executive

• Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California

  12/14/2020

  Boston Scientific Corporation announced that a stipulation of dismissal has been filed in the Nevro Corporation patent infringement case against Boston Scientific in the United States District Court for the Northern District of California.

• 

  Biopharma Money on the Move: November 25 – December 1

  12/2/2020

  A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.

• Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

  12/1/2020

  Boston Scientific Corporation announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.

• Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference

  11/23/2020

  Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1.